Seegene Reports Q3 Revenue Growth Driven by Non-Respiratory Diagnostics
Increased sales in HPV testing and European expansion offset temporary foreign exchange losses.
1Quarterly Financial Performance Overview
Seegene reported a third-quarter revenue of 123.1 billion won, marking an 8.4% increase compared to the same period last year. Operating profit reached 11.6 billion won, reflecting a 21.2% growth. These figures highlight the company's ability to scale its core diagnostic business despite broader market fluctuations and shifting regional demand patterns.
2Non-Respiratory Product Growth
The company's non-respiratory diagnostic product line generated 62.4 billion won in revenue, a 12.3% year-over-year increase. Specifically, HPV diagnostic products saw the most significant growth, rising by 19.7%. This shift indicates a successful diversification strategy beyond traditional respiratory testing, which has historically dominated the company's portfolio during the pandemic era.
3Net Loss and Currency Impact
Despite the rise in operating profit, Seegene recorded a net loss of 18.8 billion won, shifting from a 14.6 billion won profit last year. Management attributed this deficit to temporary foreign exchange losses. Since the majority of revenue is generated overseas, currency volatility remains a critical factor impacting the company's bottom-line financial results.
4European Market Strategy Shift
Europe currently accounts for 59.1% of Seegene's total revenue, making it the company's most vital market. To capture more value, Seegene is transitioning from distributor-led sales to direct sales models. In July, the French subsidiary began managing product distribution internally, a move intended to strengthen customer relationships and improve overall profit margins.
5Expansion into Public Tenders
Seegene is actively targeting public tender markets to sustain its growth trajectory. By leveraging its established HPV testing capabilities, the company aims to secure long-term contracts with public health institutions. This strategic pivot is designed to stabilize revenue streams and reduce reliance on private sector demand in highly competitive diagnostic markets.
6Future Growth and Innovation
Kim Jung-yong, Seegene’s Chief Financial Officer, emphasized that the company will continue to focus on market expansion and the advancement of next-generation diagnostic solutions. By upgrading its technological infrastructure, Seegene intends to reinforce its mid-to-long-term growth drivers, ensuring it remains competitive against global diagnostic firms in the evolving healthcare landscape.
7Context of Diagnostic Market
The diagnostic industry is currently undergoing a transition as demand for COVID-19 related products stabilizes. Companies like Seegene are pivoting toward chronic disease screening and specialized molecular diagnostics to maintain relevance. This shift requires significant investment in R&D and a robust international supply chain to support the transition to direct sales.
8Market Outlook and Implications
Investors are closely monitoring how Seegene balances its operational growth with the volatility of foreign exchange markets. While the increase in operating profit demonstrates strong product demand, the net loss highlights the risks associated with global operations. Future performance will depend on the success of the direct sales model in Europe.